ERBB3 R1202W

CI-VAR-00003631Explore in graph →CIViC 3498

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma1
ERBB3 R1202W	Cetuximab + ErlotinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID9681 In an in vitro study, an head and neck squamous cell carcinoma (HNSCC) cell line KYSE270 expressing ERBB3 (HER3) R1202W mutation was associated with insensitivity to cetuximab and erlotinib treatments… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.